- Press releases
- Events & Presentations
- Corporate Governance
- Shareholder & Stock Info
- Analyst Coverage
- Financial Reports
- Financial calendar
- DCprime Merger Information
- Secured Rights issue 2018
- Secured Rights issue 2017
Chief Executive Officer
Shares: 530,824 Ph.D. in Molecular Microbiology and M.Sc. in Medical Biology Born: 1971
Experience: Erik Manting worked for a number of years in the field of immunology before making a career switch to banking in 2001. He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare. He joined DCprime in 2017, first as business development consultant, and from March 2018 as CEO until the combination with Immunicum in December 2020.
Ongoing engagements: Supervisory board member Synerkine Pharma BV, Independent Director Transcode Therapeutics Inc.
Chief Scientific Officer
Shares: 621,736 (private and through related persons’ holdings), 184,000 (warrants) M.D., Ph.D. Adjunct Professor in Clinical Immunology, Uppsala University, Sweden Born: 1950
Experience: Alex Karlsson-Parra, MD, PhD has over 20 years of experience within transplantation immunology. In addition to his position as Co-Founder and CSO at Immunicum, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman of the Swedish Expert Group for Clinical immunology. Dr. Karlsson-Parra was awarded the Athena Prize, the Swedish healthcare´s most prestigious award for clinical research, in 2014. Prior to his current positions, he served as Associate Professor and Senior Physician at the Department of Clinical Immunology at Sahlgrenska University Hospital, Gothenburg, Sweden and Uppsala University Hospital, Sweden.
Ongoing engagements: –
Past engagements during the last five (5) years: Board member of Immunicum.
Chief Medical Officer
M.D., Ph.D., Dr. Rovers has a medical degree from Leiden University and a Ph.D. in Surgical Oncology Born: 1970
Experience: Jeroen Rovers trained as a pharmaceutical physician at the European Center of Pharmaceutical Medicine in Basel. In the past 20 years he worked in different academic institutes and companies, such as Wyeth and Organon and most recently at Kiadis Pharma where he held the role as Chief Medical Officer. Most of the products he worked on are related to oncology, haematology and transplantation. Dr. Rovers joined DCprime as Chief Medical Officer at the end of 2018 and has been serving as Managing Director for DCprime following the business combination with Immunicum in December of last year.
Degree in Business Administration and Economics from Högskolan Kristianstad and Växjö University. Born: 1966
Experience: Nearly 30 years of finance and controlling experience from a range of corporations including most recently Doktor24 Healthcare AB and Medivir AB in the healthcare and life science sectors. She has held CFO, Head of Finance and Head of Controlling positions consistently over the last decade and led the corporate finance and accounting functions for multiple transitions for dynamic and innovative companies.